Hepatitis E Diagnostic Tests Market By Test Type (ELISA HEV IgM Test, ELISA HEV IgG Test, RT-PCR Test), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Hepatitis E Diagnostic Tests Market

Hepatitis E diagnostic test market mainly involves the sales and distribution of hepatitis E diagnostic tests kits by the key market players. Hepatitis E is the infection caused by hepatitis E virus (hepevirus), which is an inflammation caused to the liver. This infection includes symptoms such nausea and jaundice which further leads to acute hepatitis in normal people and chronic hepatitis in immunosuppressed people. Furthermore, if chronic hepatitis remains undiagnosed and untreated it may lead to severe conditions such as cirrhosis and liver cancer.

World Health Organization states that around 30% (15–45%) of infected people clear the infection within 6 months of occurrence without any treatment. The remaining 70% of people may develop chronic infection, having the risk of cirrhosis ranging from 15% to 30% within 20 years. Thus, the need for early diagnosis and treatment of the condition is necessary, which further rises the demand for hepatitis E diagnostic test kits, and propels the hepatitis E diagnostic tests market growth.In addition, factors that drive the growth of the global hepatitis E diagnostic tests market trends include high prevalence of hepatitis E cases, rise in awareness about risk factors associated with hepatitis E if remained untreated, advancements in the field of diagnosis and treatment, and rise in investments by the public and private players in the R&D activities in this field.Moreover, the new product launches and product approvals by the public and private players is anticipated to provide a lucrative opportunity for the market. For instance, in August 2022, Roche announced the launch of a digital PCR system, which is a powerful new diagnostics platform in the fight against cancer and other infectious diseases. The new system has the potential to find and quantify rare and hard to detect mutations allowing for early diagnosis of severe hepatitis infections.

In addition, the government and non-government organizations in the developed as well as developing countries focus on creating awareness among the population about hepatitis diseases and related risk factors. Various campaigns and drives are arranged by different organizations which further creates awareness among the population about the causes and symptoms about the infection. It is necessary to create awareness among people about the safety of drinking water, and various methods to stop this spread of infection from drinking water, as hepatitis infection is caused due to drinking water contaminated by feces. In addition, the government have also taken initiatives to spread knowledge and information about the advanced diagnostic techniques which will help in early detection and treatment of the infection and avoid any serious conditions associated with it. This, further expand the market of hepatitis E diagnostic tests.

The hepatitis E diagnostic tests industry is segmented on the basis of test type, end user, and region. On the basis of test type, the market is segmented into HEV IgM ELISA Test, HEV IgG ELISA Test, and RT-PCR test. The HEV IgM ELISA Test segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to the rise in advancements in this segment which offers accurate and immediate results in diagnosis of infectious diseases.On the basis of end user, the market is categorized into hospitals, diagnostic centers and others (research centers, blood bank, point of care, standalone laboratories). In 2021, the diagnostic centers segment held the largest Hepatitis E Diagnostic tests market share of the global hepatitis E diagnostic tests market, and is expected to grow at the highest CAGR during the forecast period. Increase in patient visits to the diagnostic centers after the COVID-19 pandemic as they offer the precise testing and thus assist the healthcare provider to decide the treatment regime.

Asia-Pacific acquired the major share of the hepatitis E diagnostic tests market in 2021, is expected to register highest CAGR from 2022 to 2031, owing to the rapid changes in the environmental conditions and associated viral and bacterial infections which leads to severe viral endemics in this region.

Key findings of the study

By test type, the HEV IgM ELISA Test segment was the highest contributor to the market in 2021.

By end user, the diagnostic centers segment held the highest position in terms of revenue in 2021, and are expected to grow at the highest CAGR during the forecast period

Region wise, Asia-Pacific garnered the largest revenue share in 2021, and is anticipated to grow at the highest CAGR during the forecast period.

Overview

The global hepatitis E diagnostic tests market was valued at $61.69 million in 2021, and is projected to reach $93.5 million by 2031, registering a CAGR of 4.2% from 2022 to 2031.

Hepatitis E is a type of viral infection which leads to liver inflammation caused due to hepatitis E virus (HEV). Hepatitis E virus is a positive-sense, single-stranded, non-enveloped, RNA icosahedral virus and is one of the five known human hepatitis virus (A, B, C, D, and E). The transmission of hepatitis E infection occurs through oral or fecal route which is similar to that of hepatitis A. This condition is temporary and can be treated and recovered if diagnosed at an early stage. However, the infection may lead to serious effects in pregnant women and people with weak immune system, which may further lead to death.

Symptoms of hepatitis E infection are asymptomatic in acute cases, however in some cases the patient may suffer from jaundice, fatigue and nausea. It also includes chronic conditions such as fulminant liver failure or liver cirrhosis which are mainly seen in patients with weakened immune systems and who had a solid organ transplant. There is need for early detection and treatment of the infection, which leads to rise in demands for hepatitis E diagnostics kits as the condition may be life threatening in some cases.

According to World Health Organization (WHO), thousands of acute viral hepatitis infections affect children, adolescents and adults every year which may cause mild diseases and even go undetected. However, in some cases, they can cause severe complications and lead to the death of the person.

It also states that in 2019 alone, an estimated 78,000 deaths occurred due to complications of acute hepatitis A to E infections around the globe. This highlights the rise in number of hepatitis infections in population, which further demands for early diagnosis of the condition. This further propels the sale of hepatitis E diagnostic test kits and subsequently the growth of hepatitis E diagnostic tests market.

Furthermore, certain group of population is at high risk of hepatitis E infection, which includes pregnant women, immunosuppressed people, and people with pre-existing liver disease. Pregnant women are majorly at higher risk of getting HEV genotype 1 infection which is associated with fulminant hepatitis and leads to death in women. In addition, women in second or third trimester are at higher risk of acute liver failure, fetal loss and mortality due to hepatitis E. World Health Organization further states that up to 20–25% of pregnant women can die due to hepatitis E in third trimester of pregnancy. Thus, efficient diagnosis and treatment of the condition is necessary to reduce the mortality rate in pregnant women associated with hepatitis E, which propels the growth of hepatitis E diagnostic tests market.

Furthermore, advancements in the field of diagnosis and treatments drive the market. Several advancements have been done by the researchers and manufacturers in healthcare sector which makes the diagnosis and treatment procedure more efficient and accurate. The development of nucleic acid testing kits and enzyme-linked immunosorbent assay (ELISA) kits, which is based on the detection of specific anti-HEV immunoglobulin M (IgM) antibodies to the virus in the blood of a person, offers high quality, efficiency and accuracy in results. For instance, Human Hepatitis E Virus Antibody (IgG) ELISA Kit offered by Cusabio Technology Llc. is used in the detection of HEV IgG antibody in the serum and plasma and is based on qualitative enzyme immunoassay technique.

Such, new and advanced diagnostic tests kits offered by manufacturers increase the demand for the hepatitis E diagnostics tests kits and accelerate the market growth.Furthermore, rise in funds by governments of various countries and non-government organizations to initiate manufacturing units in the healthcare sector are expected to boost the market growth. Moreover, acquisition and partnerships strategies adopted by key market players are boosting factors for the market.

However, hepatitis E diagnostic kits have limited shelf life. Therefore, there is a crucial need to manage the storage of these kits. In addition, these ELISA kits are to be handled with care, as minor changes in the kit may lead to inaccuracies in range, sensitivity, and precision which provides hindrance to the hepatitis E diagnostic tests market growth. On the contrary, rise in the research and development activities by the key market players and increase in healthcare expenditure have further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the hepatitis E diagnostic tests market.

The hepatitis E diagnostic tests market is segmented on the basis of, test type, end user and region. On the basis of test type, the market is categorized into HEV IgM ELISA Test, HEV IgG ELISA Test, and RT-PCR Test. On the basis of end user, it is segmented into hospitals, diagnostic centers and others (research centers, blood bank, point of care, standalone laboratories). On the basis of region, it is studied across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global hepatitis E diagnostic tests market are Altona Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd, Dia.Pro Diagnostic Bioprobes s.r.l, ELITechGroup, PerkinElmer Inc. (Euroimmun Medizinische Labordiagnostika AG), F. Hoffmann-La Roche Ltd., Fortress Diagnostics, Mikrogen Diagnostik, MP Biomedicals , Primerdesign Ltd. and others.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis e diagnostic tests market analysis from 2021 to 2031 to identify the prevailing hepatitis e diagnostic tests market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the hepatitis e diagnostic tests market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global hepatitis e diagnostic tests market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Beijing Wantai Biolog Pha Ent Co Lt

Scope of Hepatitis E Diagnostic Tests Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Market dynamics

3.4.1.Drivers

3.4.2.Restraints

3.4.3.Opportunities

3.5.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2. ELISA HEV IgM Test

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.3. ELISA HEV IgG Test

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

4.4. RT-PCR Test

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2. Hospitals

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3. Diagnostic Centers

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

5.4. Others

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key trends and opportunities

6.2.2 North America Market size and forecast, by Test Type

6.2.3 North America Market size and forecast, by End User

6.2.4 North America Market size and forecast, by country

6.2.4.1 U.S.

6.2.4.1.1 Key market trends, growth factors and opportunities

6.2.4.1.2 Market size and forecast, by Test Type

6.2.4.1.3 Market size and forecast, by End User

6.2.4.2 Canada

6.2.4.2.1 Key market trends, growth factors and opportunities

6.2.4.2.2 Market size and forecast, by Test Type

6.2.4.2.3 Market size and forecast, by End User

6.2.4.3 Mexico

6.2.4.3.1 Key market trends, growth factors and opportunities

6.2.4.3.2 Market size and forecast, by Test Type

6.2.4.3.3 Market size and forecast, by End User

6.3 Europe

6.3.1 Key trends and opportunities

6.3.2 Europe Market size and forecast, by Test Type

6.3.3 Europe Market size and forecast, by End User

6.3.4 Europe Market size and forecast, by country

6.3.4.1 Germany

6.3.4.1.1 Key market trends, growth factors and opportunities

6.3.4.1.2 Market size and forecast, by Test Type

6.3.4.1.3 Market size and forecast, by End User

6.3.4.2 France

6.3.4.2.1 Key market trends, growth factors and opportunities

6.3.4.2.2 Market size and forecast, by Test Type

6.3.4.2.3 Market size and forecast, by End User

6.3.4.3 UK

6.3.4.3.1 Key market trends, growth factors and opportunities

6.3.4.3.2 Market size and forecast, by Test Type

6.3.4.3.3 Market size and forecast, by End User

6.3.4.4 Italy

6.3.4.4.1 Key market trends, growth factors and opportunities

6.3.4.4.2 Market size and forecast, by Test Type

6.3.4.4.3 Market size and forecast, by End User

6.3.4.5 Spain

6.3.4.5.1 Key market trends, growth factors and opportunities

6.3.4.5.2 Market size and forecast, by Test Type

6.3.4.5.3 Market size and forecast, by End User

6.3.4.6 Rest of Europe

6.3.4.6.1 Key market trends, growth factors and opportunities

6.3.4.6.2 Market size and forecast, by Test Type

6.3.4.6.3 Market size and forecast, by End User

6.4 Asia-Pacific

6.4.1 Key trends and opportunities

6.4.2 Asia-Pacific Market size and forecast, by Test Type

6.4.3 Asia-Pacific Market size and forecast, by End User

6.4.4 Asia-Pacific Market size and forecast, by country

6.4.4.1 Japan

6.4.4.1.1 Key market trends, growth factors and opportunities

6.4.4.1.2 Market size and forecast, by Test Type

6.4.4.1.3 Market size and forecast, by End User

6.4.4.2 China

6.4.4.2.1 Key market trends, growth factors and opportunities

6.4.4.2.2 Market size and forecast, by Test Type

6.4.4.2.3 Market size and forecast, by End User

6.4.4.3 Australia

6.4.4.3.1 Key market trends, growth factors and opportunities

6.4.4.3.2 Market size and forecast, by Test Type

6.4.4.3.3 Market size and forecast, by End User

6.4.4.4 India

6.4.4.4.1 Key market trends, growth factors and opportunities

6.4.4.4.2 Market size and forecast, by Test Type

6.4.4.4.3 Market size and forecast, by End User

6.4.4.5 South Korea

6.4.4.5.1 Key market trends, growth factors and opportunities

6.4.4.5.2 Market size and forecast, by Test Type

6.4.4.5.3 Market size and forecast, by End User

6.4.4.6 Rest of Asia-Pacific

6.4.4.6.1 Key market trends, growth factors and opportunities

6.4.4.6.2 Market size and forecast, by Test Type

6.4.4.6.3 Market size and forecast, by End User

6.5 LAMEA

6.5.1 Key trends and opportunities

6.5.2 LAMEA Market size and forecast, by Test Type

6.5.3 LAMEA Market size and forecast, by End User

6.5.4 LAMEA Market size and forecast, by country

6.5.4.1 Brazil

6.5.4.1.1 Key market trends, growth factors and opportunities

6.5.4.1.2 Market size and forecast, by Test Type

6.5.4.1.3 Market size and forecast, by End User

6.5.4.2 Saudi Arabia

6.5.4.2.1 Key market trends, growth factors and opportunities

6.5.4.2.2 Market size and forecast, by Test Type

6.5.4.2.3 Market size and forecast, by End User

6.5.4.3 South Africa

6.5.4.3.1 Key market trends, growth factors and opportunities

6.5.4.3.2 Market size and forecast, by Test Type

6.5.4.3.3 Market size and forecast, by End User

6.5.4.4 Rest of LAMEA

6.5.4.4.1 Key market trends, growth factors and opportunities

6.5.4.4.2 Market size and forecast, by Test Type

6.5.4.4.3 Market size and forecast, by End User

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Top player positioning, 2021

8.1 MP Biomedicals LLP

8.1.1 Company overview

8.1.2 Key Executives

8.1.3 Company snapshot

8.1.4 Operating business segments

8.1.5 Product portfolio

8.1.6 Business performance

8.1.7 Key strategic moves and developments

8.2 F. Hoffmann-La Roche Ltd.

8.2.1 Company overview

8.2.2 Key Executives

8.2.3 Company snapshot

8.2.4 Operating business segments

8.2.5 Product portfolio

8.2.6 Business performance

8.2.7 Key strategic moves and developments

8.3 Altona Diagnostics

8.3.1 Company overview

8.3.2 Key Executives

8.3.3 Company snapshot

8.3.4 Operating business segments

8.3.5 Product portfolio

8.3.6 Business performance

8.3.7 Key strategic moves and developments

8.4 PerkinElmer, Inc

8.4.1 Company overview

8.4.2 Key Executives

8.4.3 Company snapshot

8.4.4 Operating business segments

8.4.5 Product portfolio

8.4.6 Business performance

8.4.7 Key strategic moves and developments

8.5 Dia.Pro - Diagnostic Bioprobes s.r.l

8.5.1 Company overview

8.5.2 Key Executives

8.5.3 Company snapshot

8.5.4 Operating business segments

8.5.5 Product portfolio

8.5.6 Business performance

8.5.7 Key strategic moves and developments

8.6 Primerdesign Ltd

8.6.1 Company overview

8.6.2 Key Executives

8.6.3 Company snapshot

8.6.4 Operating business segments

8.6.5 Product portfolio

8.6.6 Business performance

8.6.7 Key strategic moves and developments

8.7 Mikrogen GmbH

8.7.1 Company overview

8.7.2 Key Executives

8.7.3 Company snapshot

8.7.4 Operating business segments

8.7.5 Product portfolio

8.7.6 Business performance

8.7.7 Key strategic moves and developments

8.8 Fortress Diagnostics

8.8.1 Company overview

8.8.2 Key Executives

8.8.3 Company snapshot

8.8.4 Operating business segments

8.8.5 Product portfolio

8.8.6 Business performance

8.8.7 Key strategic moves and developments

8.9 ELITechGroup

8.9.1 Company overview

8.9.2 Key Executives

8.9.3 Company snapshot

8.9.4 Operating business segments

8.9.5 Product portfolio

8.9.6 Business performance

8.9.7 Key strategic moves and developments

8.10 Beijing Wantai Biolog Pha Ent Co Ltd

8.10.1 Company overview

8.10.2 Key Executives

8.10.3 Company snapshot

8.10.4 Operating business segments

8.10.5 Product portfolio

8.10.6 Business performance

8.10.7 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 2. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR ELISA HEV IGM TEST, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR ELISA HEV IGG TEST, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 4. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR RT-PCR TEST, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 5. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 6. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 7. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 8. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 9. HEPATITIS E DIAGNOSTIC TESTS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 10. NORTH AMERICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 11. NORTH AMERICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 12. NORTH AMERICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 13. U.S. HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 14. U.S. HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 15. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 16. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 17. MEXICO HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 18. MEXICO HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 19. EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 20. EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 21. EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 22. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 23. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 24. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 25. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 26. UK HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 27. UK HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 28. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 29. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 30. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 31. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 32. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 33. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 34. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 35. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 36. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 37. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 38. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 39. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 40. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 41. AUSTRALIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 42. AUSTRALIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 43. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 44. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 45. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 46. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 47. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 48. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 49. LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 50. LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 51. LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 52. BRAZIL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 53. BRAZIL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 54. SAUDI ARABIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 55. SAUDI ARABIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 56. SOUTH AFRICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 57. SOUTH AFRICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 58. REST OF LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 59. REST OF LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 60. MP BIOMEDICALS LLP: KEY EXECUTIVES

TABLE 61. MP BIOMEDICALS LLP: COMPANY SNAPSHOT

TABLE 62. MP BIOMEDICALS LLP: OPERATING SEGMENTS

TABLE 63. MP BIOMEDICALS LLP: PRODUCT PORTFOLIO

TABLE 64. MP BIOMEDICALS LLP: NET SALES

TABLE 65. MP BIOMEDICALS LLP: KEY STRATERGIES

TABLE 66. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 67. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 68. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS

TABLE 69. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 70. F. HOFFMANN-LA ROCHE LTD.: NET SALES

TABLE 71. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES

TABLE 72. ALTONA DIAGNOSTICS: KEY EXECUTIVES

TABLE 73. ALTONA DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 74. ALTONA DIAGNOSTICS: OPERATING SEGMENTS

TABLE 75. ALTONA DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 76. ALTONA DIAGNOSTICS: NET SALES

TABLE 77. ALTONA DIAGNOSTICS: KEY STRATERGIES

TABLE 78. PERKINELMER, INC: KEY EXECUTIVES

TABLE 79. PERKINELMER, INC: COMPANY SNAPSHOT

TABLE 80. PERKINELMER, INC: OPERATING SEGMENTS

TABLE 81. PERKINELMER, INC: PRODUCT PORTFOLIO

TABLE 82. PERKINELMER, INC: NET SALES

TABLE 83. PERKINELMER, INC: KEY STRATERGIES

TABLE 84. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: KEY EXECUTIVES

TABLE 85. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: COMPANY SNAPSHOT

TABLE 86. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: OPERATING SEGMENTS

TABLE 87. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: PRODUCT PORTFOLIO

TABLE 88. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: NET SALES

TABLE 89. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: KEY STRATERGIES

TABLE 90. PRIMERDESIGN LTD: KEY EXECUTIVES

TABLE 91. PRIMERDESIGN LTD: COMPANY SNAPSHOT

TABLE 92. PRIMERDESIGN LTD: OPERATING SEGMENTS

TABLE 93. PRIMERDESIGN LTD: PRODUCT PORTFOLIO

TABLE 94. PRIMERDESIGN LTD: NET SALES

TABLE 95. PRIMERDESIGN LTD: KEY STRATERGIES

TABLE 96. MIKROGEN GMBH: KEY EXECUTIVES

TABLE 97. MIKROGEN GMBH: COMPANY SNAPSHOT

TABLE 98. MIKROGEN GMBH: OPERATING SEGMENTS

TABLE 99. MIKROGEN GMBH: PRODUCT PORTFOLIO

TABLE 100. MIKROGEN GMBH: NET SALES

TABLE 101. MIKROGEN GMBH: KEY STRATERGIES

TABLE 102. FORTRESS DIAGNOSTICS: KEY EXECUTIVES

TABLE 103. FORTRESS DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 104. FORTRESS DIAGNOSTICS: OPERATING SEGMENTS

TABLE 105. FORTRESS DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 106. FORTRESS DIAGNOSTICS: NET SALES

TABLE 107. FORTRESS DIAGNOSTICS: KEY STRATERGIES

TABLE 108. ELITECHGROUP: KEY EXECUTIVES

TABLE 109. ELITECHGROUP: COMPANY SNAPSHOT

TABLE 110. ELITECHGROUP: OPERATING SEGMENTS

TABLE 111. ELITECHGROUP: PRODUCT PORTFOLIO

TABLE 112. ELITECHGROUP: NET SALES

TABLE 113. ELITECHGROUP: KEY STRATERGIES

TABLE 114. BEIJING WANTAI BIOLOG PHA ENT CO LTD: KEY EXECUTIVES

TABLE 115. BEIJING WANTAI BIOLOG PHA ENT CO LTD: COMPANY SNAPSHOT

TABLE 116. BEIJING WANTAI BIOLOG PHA ENT CO LTD: OPERATING SEGMENTS

TABLE 117. BEIJING WANTAI BIOLOG PHA ENT CO LTD: PRODUCT PORTFOLIO

TABLE 118. BEIJING WANTAI BIOLOG PHA ENT CO LTD: NET SALES

TABLE 119. BEIJING WANTAI BIOLOG PHA ENT CO LTD: KEY STRATERGIES LIST OF FIGURES

FIGURE 1. SEGMENTATION OF HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031

FIGURE 2. HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031

FIGURE 3. TOP INVESTMENT POCKETS, BY REGION

FIGURE 4. PORTER FIVE-1

FIGURE 5. PORTER FIVE-2

FIGURE 6. PORTER FIVE-3

FIGURE 7. PORTER FIVE-4

FIGURE 8. PORTER FIVE-5

FIGURE 9. HEPATITIS E DIAGNOSTIC TESTS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. HEPATITIS E DIAGNOSTIC TESTS MARKET,BY TEST TYPE,2021(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ELISA HEV IGM TEST HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ELISA HEV IGG TEST HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RT-PCR TEST HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)

FIGURE 14. HEPATITIS E DIAGNOSTIC TESTS MARKET,BY END USER,2021(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HOSPITALS HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTERS HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OTHERS HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)

FIGURE 18. HEPATITIS E DIAGNOSTIC TESTS MARKET BY REGION,2021

FIGURE 19. U.S. HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 20. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 21. MEXICO HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 22. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 23. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 24. UK HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 25. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 26. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 27. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 28. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 29. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 30. AUSTRALIA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 31. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 32. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 33. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 34. BRAZIL HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 35. SAUDI ARABIA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 36. SOUTH AFRICA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 37. REST OF LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)

FIGURE 38. TOP WINNING STRATEGIES, BY YEAR

FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 42. COMPETITIVE DASHBOARD

FIGURE 43. COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 44. TOP PLAYER POSITIONING, 2021

FIGURE 45. MP BIOMEDICALS LLP.: NET SALES ($MILLION)

FIGURE 46. F. HOFFMANN-LA ROCHE LTD..: NET SALES ($MILLION)

FIGURE 47. ALTONA DIAGNOSTICS.: NET SALES ($MILLION)

FIGURE 48. PERKINELMER, INC.: NET SALES ($MILLION)

FIGURE 49. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L.: NET SALES ($MILLION)

FIGURE 50. PRIMERDESIGN LTD.: NET SALES ($MILLION)

FIGURE 51. MIKROGEN GMBH.: NET SALES ($MILLION)

FIGURE 52. FORTRESS DIAGNOSTICS.: NET SALES ($MILLION)

FIGURE 53. ELITECHGROUP.: NET SALES ($MILLION)

FIGURE 54. BEIJING WANTAI BIOLOG PHA ENT CO LTD.: NET SALES ($MILLION